Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4246 to 4260 of 7677 results

  1. What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared with other psychological therapies in children aged 5 to 11 years and young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/5 Question What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural

  2. Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual care/advice for children with faltering growth?

    Recommendation ID NG75/3 Question Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual

  3. Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps, leaflets and messaging) help dental teams to provide people with support to improve their oral health?

    Recommendation ID NG30/3 Question Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps

  4. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

    Recommendation ID IPG669/1 Question Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

  5. Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic acid given indefinitely compared with zoledronic acid given for a fixed duration in patients with myeloma?

    Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic

  6. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    Recommendation ID CG148/4 Question Bladder management strategies:- What are the long-term risks and effects on quality of life of different

  7. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    Recommendation ID CG146/4 Question Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of

  8. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...

  9. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    Recommendation ID CG191/4 Question Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum

  10. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

  11. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    Recommendation ID NG196/7 Question Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people